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Abstract 
 Data on the course of major depressive disorder (MDD) among people living with HIV (PLWH) are  
needed to inform refinement of screening and interventions for MDD. This paper describes the 
incidence and persistence rate of MDD in PLWH in Uganda. 1099 ART-naïve PLWH attending HIV 
clinics in Uganda were followed up for 12 months. MDD was assessed using the DSM IV based 
Mini-International Neuropsychiatric Interview with a prevalence for MDD at baseline of 14.0% (95% 
CI11.7% -16.3%) reported. Multivariable logistic regression was used to determine predictors of 
incident and persistent MDD. Cumulative incidence of MDD was 6.1 per 100 person-years (95%CI 
4.6-7.8) with significant independent predictors of study site, marital status, higher baseline 
depression score and increased stress. Persistence of MDD was  24.6% (95%CI 17.9%-32.5%) with 
independent significant predictors of study site, religion,  higher baseline depression score, and 
increased weight.  Risks of incident and persistent MDD observed in this study were high. Potentially 
modifiable factors of elevated baseline depressive scores and stress (only for incident MDD) were 
important predictors of  incident and persistent MDD.  
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Introduction 
Major depressive disorder (MDD) is the most common neuropsychiatric complication among people 
living with HIV (PLWH) with prevalence ranging from 8% to 60% [1-7].  Negative impacts of MDD 
among PLWH include poorer quality of life, faster HIV disease progression, higher mortality,  poor 
adherence to medication regimens, increased risky sexual behaviour, and perpetration of intimate 
partner violence [2,6-9].  Most studies of MDD among PLWH have been cross-sectional, and 
provided limited evidence on the course and aetiology of MDD due to the episodic nature of MDD 
[4,10] and the bi-directional relationship between MDD and HIV/AIDS [6]. Elucidating the course of 
MDD in HIV/AIDS and it’s predictors is important for refining screening procedures for MDD in 
HIV/AIDS and for the design and evaluation (including clinical trials) of intervention against MDD in 
HIV/AIDS. 
 Globally,  a number of longitudinal studies on MDD among PLWH have been undertaken in both 
high-income countries [5,11-15] and in low and –middle income  countries [4, 7, 9, 16-18]. However  
to date,  only two such studies have  been undertaken in sub-Saharan Africa [4,7].  Previous studies 
that have looked at the incidence of MDD in HIV/AIDS have reported rates of between 1.89 to 2.2 to 
per 100 person-years [17-18].  Most of the prospective studies (with none from a developing country 
context) that have included a non-HIV positive control group have reported no difference or only a 
slightly increased incidence of MDD associated with HIV [16-18].  From high income settings, 
predictors of  incident MDD in PLWH included advanced HIV clinical stage, more frequent clinic 
visits, multiple psychiatric comorbidity, past history of MDD and social conflict, [3,12,13].  From 
developing country settings, predictors of  incident MDD in PLWH included advanced HIV clinical 
stage, more frequent clinic visits, disability in work/social/family functioning, greater number of 
negative life events, decline in CD4 counts, HIV diagnosis made less than one year ago, being in HIV 
care for less than one year, having comorbid anxiety and female gender [4,16-18]. 
Similarly, there have been few studies on persistence of MDD among PLWH. In one of the 
pioneering studies in this area by Lyketsos and colleagues (1996) who followed up HIV positive 
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patients not on antiretroviral therapy (ART) over a 10 year period reported a dramatic sustained rise in 
depressive symptoms beginning 18 months before the development of AIDS and peaking at diagnosis 
of clinical AIDS [11]. In a more recent South African study where 29 participants with HIV and 
MDD were followed up over 6-months, the risk of persistence for MDD was 44.8% [4]. Predictors of 
persistence of MDD in HIV/AIDS include elevated depressive symptoms in early stage disease, self-
report of AIDS-related symptoms (fatigue and rash), concurrent unemployment, cigarette smoking, 
limited social supports and high baseline HIV symptom count [11,14].  
This paper will describe the epidemiology of incidence and persistence of MDD among PLWH 
followed for 12 months in Uganda.  
Methods 
Study design and Site 
This is a prospective cohort study where assessments were undertaken at baseline, 6-months and 12-
months. This study was undertaken at two specialised HIV clinics run by the AIDS Support 
Organisation (TASO)  at Entebbe (semi-urban) and Masaka (predominantly rural) [19]. The 
MRC/UVRI Uganda Research Unit (the host research institution) has an established research 
collaboration with these two study clinics. The TASO Entebbe clinic  has approximately 7,000 active 
clients of whom about 3,000 are ART-naïve while the Masaka TASO clinic has approximately 6,000 
clients of whom about 2,500 are ART-naïve.  
Sampling Procedure   
This study aimed to enrol 1100 ART naïve HIV positive adults from the TASO HIV clinics in Masaka 
and Entebbe (rural and semi-urban). We estimated that the sample size of 1100 respondents would 
allow us to estimate the actual incidence of MDD to a precision of about ± 1.4 per 100 PYO based on 
the following assumptions: the incident MDD cases will follow a Poisson distribution, baseline 
prevalence of MDD will be 11%; and incident rate of MDD will be 5 cases per 100 PYO. To obtain 
this sample, a sub-register of all active clients who were not on ART was created. From this register a 
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random sample of 550 ART naïve patients was recruited from each clinic  using a table of random 
numbers. 
The inclusion criteria for this study were: i) A person living with HIV/AIDS who was ART naïve and 
registered with the outpatient clinic at either TASO Entebbe and TASO Masaka clinics; ii) Aged at 
least 18 years old at enrolment; iii) Conversant in Luganda, the language into which the research 
protocols were translated (the majority of respondents were not conversant with English the language 
in which the standardised assessment tools were developed).  Exclusion criteria were being too sick or 
unable to understand the study instruments, and having defaulted on the most recent previous 
scheduled clinic visit.  Eligible participants were asked for written informed consent after explanation 
of the study objectives and procedures.  
Data collection tools 
The data collection tools consisted of structured and standardised locally translated psychosocial 
assessment tools most of which have previously been used among PLWH in the Ugandan setting by 
this study group [1].  The psychosocial assessment tools being employed for the first time in the 
Ugandan HIV setting were taken through a process of locally adaptation.  This involved a process of 
forward and back translation by two teams of mental health professionals conversant with both 
English and the local language of translation (Luganda) working independent of each other. At a 
consensus meeting where both these teams were represented the final back translated English version 
was then compared to the initial English version. On those items where there was wide variation in 
the two versions, a consensus position was arrived at through discussion.  The internal consistency of 
each of all the tools being used for the first time was determined by assessing their Cronbach’s alpha  
and only those tools which had Cronbach’s alpha  of at least 0.7 were included in subsequent analysis 
for this study.  
The data collection tools for this study were compiled together into the following groups: socio-
demographic factors (Group 1), HIV associated clinical factors (Group 2A), vulnerability/protective 
factors (Group 2B), stressors (Group 2C) and the outcome measures of MDD as  specified by the 
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conceptual framework for this study which is based on the stress-vulnerability model for depression 
(Figure 1) [20].  
                                                                Insert Figure 1 
 
A diagnoses of MDD was made using the DSM IV based Mini-International Neuropsychiatric 
Interview [31] while  severity of depressive symptoms was assessed using the Centre for 
Epidemiological Studies-Depression questionnaire (CES-D) [32], the rest of the  data collection tools 
are listed in Table I below. 
                                                                Insert Table I  
Statistical analysis 
There were two dependent variables: i) incident major depressive disorder(MDD) assessed at 6-
months and 12- months amongst those without MDD at baseline; and ii) persistent MDD over the 6-
12 month follow-up among those with MDD at baseline (i.e. MDD detected at either 6 or 12 month 
follow-up). Logistic regression was used to estimate odds ratios and 95%CIs.  A conceptual 
framework (see Figure 1) based on the stress-vulnerability models of depression [20] was developed a 
priori to guide the multivariable analysis [33].  Firstly, socio-demographic factors were included if 
there was at least weak evidence of a univariable association (p<0.15). Factors were retained if they 
remained with P<0.15 after adjustment for other socio-demographic factors. The liberal P-value cut-
off was used in order to ensure that all variables that could have a possible confounding effect on the 
ultimate risk factors were included [34].   
 
According to the conceptual framework, the socio-demographic variables (Group 1 variables)  may 
act on MDD through three groups of proximal factors, a set of HIV associated clinical variables 
(Group 2A), a set of vulnerability/protective variables (Group 2B), and a set of stressor variables 
(Group 2C). In turn, the HIV associated clinical variables may act through Groups 2B and 2C as well 
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as independently on MDD. Thus three second stage models were fitted, involving the selection of 
Group 1, and Group 2A, 2B or 2C variables respectively. The HIV associated clinical factors (Group 
2A), vulnerability/protective factors  (Group 2B),  and stressor factors (Group 2C)  associated with the 
outcome (P<0.15) after adjusting for the Group 1 variables and baseline CES-D score were selected 
into an initial multivariable model. The final multivariable model included variables that were 
independently associated with the outcome (P<0.10), using a backward elimination method. Part of 
the effect of the socio-demographic variables will be mediated through the vulnerability/protective 
variables, HIV associated clinical variables or through the stress variables, so the selected socio-
demographic variables were not removed from the final model to capture both their direct and indirect 
effects  [33]. For all continuous explanatory variables, we explored fractional polynomials of degrees 
1 and 2 to investigate for potential nonlinearity [34]. 
 
Ethical Considerations 
The study obtained ethical approval from the Uganda Virus Research Institute’s Science and Ethics 
Committee, the London School of Hygiene and Tropical Medicine Ethical Committee and the Uganda 
National Council of Science and Technology.  Study participants were invited to consent after being 
provided with adequate information about the study. Respondents found to have significant 
psychiatric problems were referred to the psychiatric departments at Entebbe district hospital (at the 
semi-urban site) and Masaka regional referral hospital (rural site) for further assessment and 
management. 
Results  
Of the 1099 participants assessed at baseline, 68 (6.2%) were lost to follow-up by 12 months, of 
whom 18 were confirmed to have died during the course of this study, the majority due to non HIV 
related causes. None of the factors of study site, gender, marital status and baseline MDD were 
associated with loss to follow-up. 
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Amongst the 944 participants without MDD at baseline, 920 had follow-up data, and there were 56 
incident cases over the 12 month follow-up period (6.1%; Table II).  Amongst the 155 participants 
with MDD at baseline, 146 had follow-up data, including 36 persistent cases (24.7%), including  11 
recurrent cases who were positive-negative-positive (Table II). 
                                                                Insert Table II 
 
 
Characteristics of study population 
 The majority (n=847, 77.1%)  of the study respondents were female.  The mean age was 35.1 years 
(standard deviation (SD)=9.3), and the majority were in early HIV stage disease (48.5% Stage 1; 
45.5% Stage 2; 6.0% Stage 3) with the majority having CD4 counts above 350 cells/ul (< 201 cells/ul 
=9.4%; 201-350 cells/ul =15.3%; 351-500 cells/ul =30.5%;and  >500=44.9%). 
 
Incidence of MDD and risk of persistence of MDD 
The cumulative incidence of MDD over 12 months in this study was 6.1per 100 person- years (95%CI 
4.6-7.8). The risk of persistent of MDD over 12 months was 24.6% (95%CI 17.9%-32.5%). 
 
 
Univariate predictors of incident MDD 
                                                                         Insert  Table III 
Table III shows factors associated with incident MDD. Among the socio-demographic factors, the 
only factor associated with incident MDD was study site (OR for Masaka vs Entebbe=4.35, 95%CI 
2.27-8.36).  After adjusting for study site, the following factors were associated with incident MDD: 
higher disability scores (OR=1.39, 95%CI 1.08-1.80); higher negative life events scores (OR=1.65, 
Incidence and persistence of depression in HIV in Uganda 
9 
 
95%CI 1.25-2.17); andhigher stress scores (OR=1.64, 95%CI 1.26-2.14); approaching  significance 
were  lower social support scores (OR=0.79, 95%CI 0.61-1.02) and baseline depressive symptom 
scores (OR=1.11, 95%CI 0.98-1.27).  
Univariate predictors of persistent MDD 
                                                                        Insert  Table IV 
Table IV shows univariate predictor factors that were associated with persistent MDD. Among the 
sociodemographic factors,  study site (Masaka-rural site) and religion  were marginally associated 
with persistent MDD.  Baseline depressive symptom scores were associated with persistent MDD 
after adjusting for study site and religion.  After adjusting for study site, religion and baseline 
depressive symptom score (CES-D), the following variables were marginally associated with 
persistent MDD: lower CD count,  a heavier  weight, family history of psychiatric disorder (OR=2.25, 
95%CI 0.98-5.12); higher negative life events score (OR=1.37, 95%CI 0.92-2.04) and higher stress 
scores (OR=1.34, 95%CI: 0.90-1.98).  
Multivariate predictors of both incident MDD and persistent MDD 
                                                                                   Insert Table V 
Table V shows the independent factors associated with incident MDD and persistent MDD 
respectively. Living in the rural site (Masaka) was independently associated with both incident and 
persistent MDD, as was a higher baseline CES-D score.  An increased stress score was associated 
with incident MDD (OR=1.56, 95%CI 1.18-2.05) and a heavier weight was associated with persistent 
MDD (OR=1.47, 95%CI 0.93-2.33). 
 
Discussion 
This is one of few papers that have investigated the incidence and persistence of major depressive 
disorder (MDD) and their predictors in HIV/AIDS in the sub-Saharan African setting. The loss to 
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follow-up in this study was 6.2% (equivalent to 6.2 per 100 person-years) a figure much better than 
that reported by Olley and colleagues (2006) [4] in Cape Town, South Africa (56%)  but lower than 
that reported by Elenga and colleagues (2013) [17] in Guadeloupe in central America (1.6 to 2.7 per 
100 person-years).  In this study the factors of study site, gender, marital status and baseline MDD 
were not associated with loss to follow-up.  In  Guadeloupe in central America,  Elenga and 
colleagues (2013) [17] have suggested that addiction may have been a factor in loss to follow-up in 
their study, a factor that was not investigated in this study. 
 
The incidence of MDD in HIV/AIDS in this study was 6.1 per 100 person-years) a figure higher than 
that reported in Guadeloupe in Central America (2.2 per 100 person years) [17] and French Guyana in 
South America (1.89 per 100 person years) [18], these two countries having generalised HIV 
epidemics similar to the HIV epidemic in sub-Saharan Africa. Differences in the incidence of MDD 
between this study and those two previous studies could be due to a number of factors including:  
differences in the assessment of MDD (in this study we used a DSM IV based structured interview-
the M.I.N.I. [31] while in the two previous studies they used non-structured clinical interviews); 
differences in the risk for MDD associated with the parent HIV risk group (thought to be minimal as 
the HIV epidemic in all three studies was generalised); differences in the  ecological risk factors for 
MDD and  differences in the HIV clinical stage profiles of the  three studies.  
 
Predictors of incident MDD observed in this study included:  study site (higher in the rural than urban 
site),  greater disability, higher negative life events, higher stress and approaching significance were 
lower social support and baseline depressive scores. The  independent predictors of incident MDD in 
this study were study site, elevated baseline depressive symptom scores and higher stress.  Just as in 
this study, Olley and colleagues (2006) [4] in South Africa reported that disability in work, social and 
family functioning and a greater number of negative life events were predictors of incident MDD. 
Lyketsos and colleagues (1996) [11] in the USA reported that elevated depressive symptom scores 
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were a predictor of higher rates of depression as AIDS developed. More recently, Atkinson and 
colleagues (2008) [5] reported that a past history of MDD was associated with a four-fold increased 
risk for developing incident MDD. Similar to this study, Lackner and colleagues (1993) [35] in a 
follow up study of male homosexuals at risk of HIV observed that  social support only marginally 
accounted for future MDD episodes. A previous cross sectional study by this research group in semi-
urban Entebbe (one of the study locations for this study) reported that increasing stress scores among 
HIV/AIDS patients was independently associated with prevalent MDD [1].   
 
The association between study site and incident MDD observed in this study could not readily be 
explained. A possible explanation of this finding could be that study site represents ecological risk 
factors for MDD with this risk being greater in the rural area than in the urban area. Kinyanda and 
colleagues (2011) [36] in a community study that investigated district level indices to explain 
variation of district rates of MDD reported that only district literacy rates showed a reciprocal 
relationship with district rates of MDD. Comparing the two study sites on a few of the socio-
economic indices collected in this study reveals the following pattern: on highest educational 
attainment, while 82% of study participants from Masaka (rural site) had seven years or less of formal 
education, the figure for Entebbe (semi-urban site) was 63% (a difference that was statistically 
significant); on socio-economic index (SEI), while the mean SEI of study participants from Masaka 
(rural site) was 13.9(SD=2.9) that for Entebbe (semi-urban site) was higher at 16.4 (a difference that 
was statistically significant). These results indicate that there are important socio-economic 
differences between the rural and urban study sites which may underlie the difference in incidence of 
MDD.  
 The risk of persistent of MDD over 12 months in this study was 24.6%. Olley and colleagues (2006) 
[4] in South Africa in one of the few studies in this area reported a 6-months rate of persistence of 
MDD in HIV/AIDS of 44.8%. The South African findings may have been confounded by the very 
high rate of loss to follow-up of 56%.  On the flip side, 75.4% of the MDD cases in this study 
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resolved by 12 months, the majority in less than 6 months (67%). Similar results to those observed in 
this study have been reported in a general population cohort study in the Netherlands (the NEMESIS 
Study) where Spijker and colleagues (2002) reported that 76% of their study participants recovered 
from MDD by 12 months with the majority (63%) of these recovering by 6 months [10]. Whiteford 
and colleagues (2013) in a systematic review on spontaneous remission of untreated MDD reported 
that 53% of untreated cases of MDD remitted by 12 months while 32% remitted by 6 months [37].  
 
Apart from the natural life cycle of MDD, other possible reasons for the high remission rates of MDD 
observed in this study include that all participants diagnosed with MDD were offered health education 
about MDD (psychoeducation is known to be effective against MDD [38] and then referred to the 
nearest health facility that offered mental health care. Secondly, 43% of the study participants 
initiated antiretroviral therapy (ART) during the course of this study. Initiation of ART has previously 
been reported by Wagner and colleagues (2012) in the HIV care situation of Uganda to be associated  
with a significant reduction in depressive symptoms mainly mediated through improvement in 
physical health functioning [39].  
 
In this study baseline depressive symptoms and marginally, study site (rural-urban difference), 
religion,  a heavier weight, a family history of psychiatric disorder, higher negative life events and  
higher stress were associated with persistent MDD. At multivariate analysis study site, elevated 
baseline depressive scores and a heavier weight were independently associated with persistent MDD. 
Of the observed predictor factors for persistence of MDD in HIV/AIDS in this study, only elevated 
depressive symptoms in early stage disease has previously been reported to be associated with 
persistent MDD in HIV/AIDS [11].  In this study, heavier weight was a predictor of persistence of 
MDD, an associated that has not been previously reported . Unlike the results from this study, the few 
adult prospective studies undertaken among non HIV populations reveal that MDD is more likely to 
elevate the risk of subsequent obesity than the converse [40-42]. From non HIV studies, stressful life 
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events  have been reported to be a predictor of persistent MDD [43-44].  Just like in this study where a 
family history of psychiatric disorder was associated with persistent MDD, Lieb and colleagues 
(2002) in a German community study of adolescents and young adults reported that parental 
depression was associated with a more malignant course of depressive disorders in offspring [45]. The 
association between study site and persistence of  MDD in this study probably points to the 
importance of ecological level factors in the persistence of MDD in HIV/AIDS in the African socio-
cultural context.  
 
In conclusion, on the incidence of MDD, the rate obtained in this study was higher than that reported 
in two previous studies undertaken in Guadeloupe (in Central America) and French Guyana (in South 
America),  countries with generalised HIV epidemics like that in Uganda, this probably points to 
differences in ecological risk factors for MDD. Secondly, the potentially modifiable factors of 
elevated baseline depressive scores and increased stress scores were independent predictors of 
incident MDD in this study. The  later findings have at least two implications for depression 
management, firstly, that elevated depressive scores (even those that are below the threshold for MDD 
diagnoses) are a risk factor for future MDD episodes and should therefore be screened for and 
managed. Secondly, that stress (number and severity of negative life events in the previous 6 months) 
is risk factor for future MDD episodes and hence should be included in the risk assessment for MDD 
and where elevated managed.  
 
In this study we reported rates of persistence of MDD that were similar to those reported in a non-
HIV community sample in the Netherlands.  The fact that about a quarter of the cases of MDD in this 
study were persistent at 6 months and up to 12 months and given the potentially negative clinical and 
psychosocial consequences of MDD reinforces the need to treat MDD in HIV/AIDS even in this 
African socio-cultural context. On the flip side however, given that three quarters of the cases of 
MDD remitted without instituting formal MDD treatment and given the severe challenges facing 
health systems in low and-middle income countries such as Uganda [46-47] calls for caution in the 
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recommendations we make for the management of MDD in such settings. In such settings there is 
need to institute stepped care collaborative management approach for MDD where low intensity 
therapies such as psychoeducation [48] and the Health Activity Programme [49] with demonstrated 
efficacy against MDD even when administered by lower level cadre such as general nurses and lay 
health workers can be offered to those with mild to moderate MDD and antidepressant medication and 
referral to mental health specialists offered to those with severe MDD. However, there is need for 
studies to develop and evaluate such stepped care collaborative models in the context of the health 
systems challenges facing HIV care services in sub-Saharan African settings such as those in  
Uganda.  Lastly, there is need for studies to specifically delineate the factors underlying ecological 
risk for MDD in HIV/AIDS, and more broadly, to better understand ecological correlates of mental 
illness in the African situation.  
 
As a limitations of this study, exclusion from enrolment of those with recent defaulted appointments 
may have introduced selection bias because MDD is a known risk factor for non-adherence  with 
medical treatment [50]. Secondly, in designing this study, we assumed that the majority of MDD 
episodes run a cycle of 6 months based on previous work undertaken in the west among HIV negative 
general population samples [10]. Indeed in this study, the majority of MDD episodes (67%) went into 
remission by 6 months although a small number (8.4%) went into remission between 6 and 12 
months.   
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